Celldex Therapeutics, Inc. (CLDX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celldex Therapeutics, Inc. on July 15, 2026, covering events occurring on July 10, 2026. The Company is a Delaware corporation with its principal executive offices in Hampton, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol "CLDX."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change disclosed is the announced departure of a senior executive:
- Departure: Sam Martin, Senior Vice President and Chief Financial Officer, notified the Company of his plans to retire effective on or about March 31, 2027.
- History: Mr. Martin joined the Company in April 2009 and has served as CFO since July 2017.
- Transition Plan: The Company has initiated a search for a new CFO. Mr. Martin will continue to serve in his current capacity through March 31, 2027, or until a successor begins service.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the executive departure.
Key Facts for Investor Verification
- Confirm the timeline for the search and appointment of a new Chief Financial Officer.
- Verify the specific date of Mr. Martin's final day of service (targeted as March 31, 2027).
- Review upcoming quarterly filings for any impact on financial reporting or internal controls during the transition period.